Skip to main content
. 2014 Oct;58(10):5831–5840. doi: 10.1128/AAC.02462-14

TABLE 1.

Comparison of IC50 values of antimalarials against P. falciparum isolates and the W2 reference clone

Test plate compounds GM IC50, nM
Isolate/W2 GM IC50 ratio P valuec
Isolates (range)a W2 (95% CI)b
Blinded test compounds
    Artemisone 2.4 (0.02–117.7) 1.9 (1.5–2.4) 1.3 0.004
    DHA internal control 8.0 (1.5–38.1) 5.0 (4.2–5.9) 1.6 <0.001
    AS 8.5 (0.5–52.7) 6.4 (5.0–8.1) 1.3 0.019
    DHA 11.2 (0.04–109.4) 5.2 (3.8–7.1) 2.2 <0.001
    Artemiside 15.3 (0.8–458.7) 11.2 (8.7–14.3) 1.4 0.022
    OZ277 31.3 (0.02–320.7) 38.5 (30.2–49.1) 0.8 0.726
    OZ78 755.7 (65.7–7,854) 406.7 (319.8–517.2) 1.9 0.003
Standard drug panel
    AS 5.8 (0.6–24.6) 4.7 (4.4–5.1) 1.2 <0.001
    LUM 7.4 (0.4–40.1) 6.0 (4.9–7.3) 1.2 0.002
    DHA 9.0 (0.8–30.2) 4.5 (4.1–4.9) 2.0 <0.001
    MQ 58.3 (0.7–205.5) 20.6 (18.2–23.2) 2.8 <0.001
    QN 146.1 (2.2–439.2) 149.0 (135.9–163.4) 1.0 0.878
    CQ 147.8 (4.7–786.0) 258.2 (237.7–280.5) 0.6 <0.001
a

GM IC50s were determined for a total of 200 isolates.

b

GM IC50s against W2 in the blinded test compound panel were determined from n = 51, 52, 52, 48, 52, 51, and 48 independent experiments for artemisone, DHA internal control, AS, artemiside, OZ277, and OZ78, respectively. GM IC50s in the standard drug panel against W2 were determined from 123 independent experiments.

c

P values (Mann-Whitney U test) in bold indicate a significant difference between IC50s for each evaluated antimalarial against isolates and W2.